Clovis steals march on AZ with PARP prostate approvalShares in US-based Clovis Oncology have ticked up after the biotech became the first to get a PARP Share XClovis steals march on AZ with PARP prostate approvalhttps://pharmaphorum.com/news/clovis-steals-march-on-az-with-parp-prostate-approval/
New price gets Clovis’ PARP inhibitor on the CDFNICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to Share XNew price gets Clovis’ PARP inhibitor on the CDFhttps://pharmaphorum.com/news/new-price-gets-clovis-parp-inhibitor-on-the-cdf/
Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerGlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid Share XRelief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerhttps://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/
Janssen CAR-T is Priority Medicine in EU, and moreEuropean regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage Share XJanssen CAR-T is Priority Medicine in EU, and morehttps://pharmaphorum.com/views-analysis-oncology/janssen-car-t-is-priority-medicine-in-eu-and-more/
Tesaro stock rockets as rumours of Roche takeover aboundShares in US biotech Tesaro peaked this week amid speculation that Roche is making plans to buy it. Share XTesaro stock rockets as rumours of Roche takeover aboundhttps://pharmaphorum.com/news/tesaro-stock-rockets-roche-takeover-abound/
